TWI250027B - Improved growth stimulant compositions - Google Patents

Improved growth stimulant compositions Download PDF

Info

Publication number: TWI250027B
Authority: TW; Taiwan
Prior art keywords: composition; weight; controlled release; release formulation; formulation
Prior art date: 1998-11-04

Application number

TW088119044A

Other languages

English (en)

Chinese (zh)

Inventor

Chung Shih

Thomas J Kennedy

Peter James Knight

Daniel S Robins

Zezhi Jesse Shao

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-11-04

Filing date

1999-11-02

Publication date

2006-03-01

1999-11-02 Application filed by Schering Corp filed Critical Schering Corp

2006-03-01 Application granted granted Critical

2006-03-01 Publication of TWI250027B publication Critical patent/TWI250027B/zh

Links

239000000203 mixture Substances 0.000 title claims abstract description 125
230000012010 growth Effects 0.000 title claims abstract description 47
230000001976 improved effect Effects 0.000 title abstract description 5
238000009472 formulation Methods 0.000 claims abstract description 78
239000003263 anabolic agent Substances 0.000 claims abstract description 74
238000013270 controlled release Methods 0.000 claims abstract description 54
239000012729 immediate-release (IR) formulation Substances 0.000 claims abstract description 32
241001465754 Metazoa Species 0.000 claims abstract description 28
241000283690 Bos taurus Species 0.000 claims abstract description 21
238000002347 injection Methods 0.000 claims abstract description 9
239000007924 injection Substances 0.000 claims abstract description 9
102000004169 proteins and genes Human genes 0.000 claims description 72
108090000623 proteins and genes Proteins 0.000 claims description 72
238000000034 method Methods 0.000 claims description 35
239000003795 chemical substances by application Substances 0.000 claims description 27
239000006187 pill Substances 0.000 claims description 23
230000001195 anabolic effect Effects 0.000 claims description 19
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 16
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 16
239000001856 Ethyl cellulose Substances 0.000 claims description 14
229920001249 ethyl cellulose Polymers 0.000 claims description 14
235000019325 ethyl cellulose Nutrition 0.000 claims description 14
239000008101 lactose Substances 0.000 claims description 14
239000003085 diluting agent Substances 0.000 claims description 12
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 11
229920001577 copolymer Polymers 0.000 claims description 11
229920002678 cellulose Polymers 0.000 claims description 6
239000001913 cellulose Substances 0.000 claims description 6
239000003153 chemical reaction reagent Substances 0.000 claims description 6
239000000546 pharmaceutical excipient Substances 0.000 claims description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
229920002472 Starch Polymers 0.000 claims description 5
235000013305 food Nutrition 0.000 claims description 5
-1 hydroxypropyl decyl Chemical group 0.000 claims description 5
239000008107 starch Substances 0.000 claims description 5
235000019698 starch Nutrition 0.000 claims description 5
230000000638 stimulation Effects 0.000 claims description 5
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
239000004375 Dextrin Substances 0.000 claims description 3
229920001353 Dextrin Polymers 0.000 claims description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
229930195725 Mannitol Natural products 0.000 claims description 3
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 3
229930006000 Sucrose Natural products 0.000 claims description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
235000019425 dextrin Nutrition 0.000 claims description 3
239000008103 glucose Substances 0.000 claims description 3
239000000594 mannitol Substances 0.000 claims description 3
235000010355 mannitol Nutrition 0.000 claims description 3
229920000609 methyl cellulose Polymers 0.000 claims description 3
239000001923 methylcellulose Substances 0.000 claims description 3
229910052709 silver Inorganic materials 0.000 claims description 3
239000004332 silver Substances 0.000 claims description 3
239000005720 sucrose Substances 0.000 claims description 3
230000007794 irritation Effects 0.000 claims description 2
238000011068 loading method Methods 0.000 claims description 2
239000004354 Hydroxyethyl cellulose Substances 0.000 claims 3
229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 3
235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 3
239000011230 binding agent Substances 0.000 claims 2
239000003086 colorant Substances 0.000 claims 2
239000000945 filler Substances 0.000 claims 2
235000010981 methylcellulose Nutrition 0.000 claims 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
239000001768 carboxy methyl cellulose Substances 0.000 claims 1
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
IQSHMXAZFHORGY-UHFFFAOYSA-N methyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound COC(=O)C=C.CC(=C)C(O)=O IQSHMXAZFHORGY-UHFFFAOYSA-N 0.000 claims 1
239000000843 powder Substances 0.000 claims 1
239000011734 sodium Substances 0.000 claims 1
229910052708 sodium Inorganic materials 0.000 claims 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 1
238000010254 subcutaneous injection Methods 0.000 claims 1
239000007929 subcutaneous injection Substances 0.000 claims 1
125000003396 thiol group Chemical class [H]S* 0.000 claims 1
229940124325 anabolic agent Drugs 0.000 abstract description 24
230000009977 dual effect Effects 0.000 abstract description 10
241001494479 Pecora Species 0.000 abstract description 3
241000282887 Suidae Species 0.000 abstract description 2
239000007943 implant Substances 0.000 abstract description 2
FPQFYIAXQDXNOR-QDKLYSGJSA-N alpha-Zearalenol Chemical compound O=C1O[C@@H](C)CCC[C@H](O)CCC\C=C\C2=CC(O)=CC(O)=C21 FPQFYIAXQDXNOR-QDKLYSGJSA-N 0.000 abstract 1
229960002300 zeranol Drugs 0.000 abstract 1
230000004584 weight gain Effects 0.000 description 18
235000019786 weight gain Nutrition 0.000 description 18
239000011159 matrix material Substances 0.000 description 16
239000005556 hormone Substances 0.000 description 15
229940088597 hormone Drugs 0.000 description 15
239000003826 tablet Substances 0.000 description 14
239000003814 drug Substances 0.000 description 12
229940079593 drug Drugs 0.000 description 10
150000003431 steroids Chemical class 0.000 description 9
229920000642 polymer Polymers 0.000 description 8
230000000694 effects Effects 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
DWTTZBARDOXEAM-GXTWGEPZSA-N alpha-Zearalanol Chemical compound O=C1O[C@@H](C)CCC[C@H](O)CCCCCC2=CC(O)=CC(O)=C21 DWTTZBARDOXEAM-GXTWGEPZSA-N 0.000 description 6
230000007774 longterm Effects 0.000 description 6
229940115271 ralgro Drugs 0.000 description 6
229920002988 biodegradable polymer Polymers 0.000 description 5
239000004621 biodegradable polymer Substances 0.000 description 5
244000144972 livestock Species 0.000 description 5
239000000463 material Substances 0.000 description 5
230000002503 metabolic effect Effects 0.000 description 5
239000002904 solvent Substances 0.000 description 5
238000013268 sustained release Methods 0.000 description 5
239000012730 sustained-release form Substances 0.000 description 5
230000015556 catabolic process Effects 0.000 description 4
238000006731 degradation reaction Methods 0.000 description 4
238000011161 development Methods 0.000 description 4
239000008187 granular material Substances 0.000 description 4
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
239000000902 placebo Substances 0.000 description 4
229940068196 placebo Drugs 0.000 description 4
230000004936 stimulating effect Effects 0.000 description 4
239000000126 substance Substances 0.000 description 4
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
230000037396 body weight Effects 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
238000013461 design Methods 0.000 description 3
239000000975 dye Substances 0.000 description 3
239000007952 growth promoter Substances 0.000 description 3
239000000314 lubricant Substances 0.000 description 3
239000011859 microparticle Substances 0.000 description 3
239000008188 pellet Substances 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
239000000047 product Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
238000012546 transfer Methods 0.000 description 3
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
206010036790 Productive cough Diseases 0.000 description 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
238000004040 coloring Methods 0.000 description 2
238000007906 compression Methods 0.000 description 2
230000006835 compression Effects 0.000 description 2
DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
229960005309 estradiol Drugs 0.000 description 2
229930182833 estradiol Natural products 0.000 description 2
230000036571 hydration Effects 0.000 description 2
238000006703 hydration reaction Methods 0.000 description 2
239000004310 lactic acid Substances 0.000 description 2
235000014655 lactic acid Nutrition 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
239000002245 particle Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
210000003802 sputum Anatomy 0.000 description 2
208000024794 sputum Diseases 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000000052 vinegar Substances 0.000 description 2
235000021419 vinegar Nutrition 0.000 description 2
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
208000000412 Avitaminosis Diseases 0.000 description 1
241001674044 Blattodea Species 0.000 description 1
WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
229930182843 D-Lactic acid Natural products 0.000 description 1
JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000283086 Equidae Species 0.000 description 1
GISRWBROCYNDME-PELMWDNLSA-N F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C Chemical compound F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C GISRWBROCYNDME-PELMWDNLSA-N 0.000 description 1
108091006027 G proteins Proteins 0.000 description 1
102000030782 GTP binding Human genes 0.000 description 1
108091000058 GTP-Binding Proteins 0.000 description 1
102000018997 Growth Hormone Human genes 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
206010021135 Hypovitaminosis Diseases 0.000 description 1
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
229920001046 Nanocellulose Polymers 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
RRDBGKFTNJDTBK-WAJSLEGFSA-N OC(=O)C1=CC=CC=C1.OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)O)[C@@H]4[C@@H]3CCC2=C1 Chemical compound OC(=O)C1=CC=CC=C1.OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)O)[C@@H]4[C@@H]3CCC2=C1 RRDBGKFTNJDTBK-WAJSLEGFSA-N 0.000 description 1
235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
244000046052 Phaseolus vulgaris Species 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
101100463797 Rattus norvegicus Pgrmc1 gene Proteins 0.000 description 1
GHMLBKRAJCXXBS-UHFFFAOYSA-N Resorcinol Natural products OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
PXAJQJMDEXJWFB-UHFFFAOYSA-N acetone oxime Chemical compound CC(C)=NO PXAJQJMDEXJWFB-UHFFFAOYSA-N 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
244000309466 calf Species 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
230000000711 cancerogenic effect Effects 0.000 description 1
231100000315 carcinogenic Toxicity 0.000 description 1
230000008859 change Effects 0.000 description 1
238000007334 copolymerization reaction Methods 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
150000004292 cyclic ethers Chemical class 0.000 description 1
230000000593 degrading effect Effects 0.000 description 1
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
150000002013 dioxins Chemical class 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000000605 extraction Methods 0.000 description 1
230000035611 feeding Effects 0.000 description 1
239000012467 final product Substances 0.000 description 1
230000002431 foraging effect Effects 0.000 description 1
239000013022 formulation composition Substances 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000002363 herbicidal effect Effects 0.000 description 1
239000004009 herbicide Substances 0.000 description 1
244000144980 herd Species 0.000 description 1
229920001519 homopolymer Polymers 0.000 description 1
238000002657 hormone replacement therapy Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
238000005461 lubrication Methods 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
235000013372 meat Nutrition 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
AXLHVTKGDPVANO-UHFFFAOYSA-N methyl 2-amino-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound COC(=O)C(N)CNC(=O)OC(C)(C)C AXLHVTKGDPVANO-UHFFFAOYSA-N 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
239000008267 milk Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
230000003020 moisturizing effect Effects 0.000 description 1
239000004570 mortar (masonry) Substances 0.000 description 1
238000000465 moulding Methods 0.000 description 1
230000021332 multicellular organism growth Effects 0.000 description 1
FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
229960002748 norepinephrine Drugs 0.000 description 1
VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
229940070020 other anabolic agent in atc Drugs 0.000 description 1
239000000049 pigment Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
239000002745 poly(ortho ester) Substances 0.000 description 1
229920001610 polycaprolactone Polymers 0.000 description 1
239000004632 polycaprolactone Substances 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
230000022558 protein metabolic process Effects 0.000 description 1
239000012748 slip agent Substances 0.000 description 1
238000007711 solidification Methods 0.000 description 1
230000008023 solidification Effects 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
230000001839 systemic circulation Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229960003604 testosterone Drugs 0.000 description 1
229960001712 testosterone propionate Drugs 0.000 description 1
208000030401 vitamin deficiency disease Diseases 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000002023 wood Substances 0.000 description 1
239000002446 δ-tocopherol Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Dermatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Medicinal Preparation (AREA)
Fodder In General (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Feed For Specific Animals (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

TW088119044A 1998-11-04 1999-11-02 Improved growth stimulant compositions TWI250027B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US18594498A	1998-11-04	1998-11-04

Publications (1)

Publication Number	Publication Date
TWI250027B true TWI250027B (en)	2006-03-01

Family

ID=22683037

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW088119044A TWI250027B (en)	1998-11-04	1999-11-02	Improved growth stimulant compositions

Country Status (11)

Country	Link
AR (1)	AR025133A1 (pt)
AU (1)	AU777393B2 (pt)
BR (2)	BRPI9914996B8 (pt)
CA (1)	CA2348841C (pt)
CO (1)	CO5140100A1 (pt)
CR (1)	CR6351A (pt)
MY (1)	MY134868A (pt)
PE (1)	PE20001092A1 (pt)
TW (1)	TWI250027B (pt)
WO (1)	WO2000025743A2 (pt)
ZA (1)	ZA200103494B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020131988A1 (en) *	1999-12-16	2002-09-19	Foster Todd P.	Pharmaceutical implant containing immediate-release and sustained-release components and method of administration
US6953586B1 (en) *	2000-06-08	2005-10-11	Ivy Animal Health, Inc.	Growth promoting pharmaceutical implant
EP4000688B1 (en)	2020-11-19	2025-11-05	F.I.S.- Fabbrica Italiana Sintetici S.p.A.	Process for the preparation of trenbolone acetate having a definite particle size distribution
EP4001289B1 (en)	2020-11-19	2023-05-03	F.I.S.- Fabbrica Italiana Sintetici S.p.A.	Improved process for the preparation of trenbolone and/or trenbolone acetate
EP4001288B1 (en)	2020-11-19	2025-05-07	F.I.S.- Fabbrica Italiana Sintetici S.p.A.	Process for the preparation of trenbolone acetate having a definite particle size distribution and a irregular hexagon plates crystal habit

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2573307B1 (fr) *	1984-11-22	1988-06-10	Virbac Ctre Rech Biolog	Implants anabolisants a liberation prolongee
US4670249A (en) *	1985-04-12	1987-06-02	International Minerals & Chemical Corp.	Growth-promoting compositions
US5219572A (en) *	1989-03-17	1993-06-15	Pitman-Moore, Inc.	Controlled release delivery device for macromolecular proteins
US5747060A (en) *	1996-03-26	1998-05-05	Euro-Celtique, S.A.	Prolonged local anesthesia with colchicine
US5874098A (en) *	1997-05-28	1999-02-23	Ivy Laboratories, Inc.	Pellet implant system

1999
- 1999-11-02 CO CO99069032A patent/CO5140100A1/es unknown
- 1999-11-02 WO PCT/US1999/023993 patent/WO2000025743A2/en not_active Ceased
- 1999-11-02 AU AU30967/00A patent/AU777393B2/en not_active Expired
- 1999-11-02 BR BRPI9914996-6 patent/BRPI9914996B8/pt unknown
- 1999-11-02 CA CA002348841A patent/CA2348841C/en not_active Expired - Lifetime
- 1999-11-02 TW TW088119044A patent/TWI250027B/zh not_active IP Right Cessation
- 1999-11-02 AR ARP990105535A patent/AR025133A1/es active IP Right Grant
- 1999-11-02 BR BR9914996-6A patent/BR9914996A/pt not_active IP Right Cessation
- 1999-11-03 PE PE1999001104A patent/PE20001092A1/es not_active IP Right Cessation
- 1999-11-03 MY MYPI99004773A patent/MY134868A/en unknown
2001
- 2001-04-20 CR CR6351A patent/CR6351A/es not_active Application Discontinuation
- 2001-04-30 ZA ZA200103494A patent/ZA200103494B/xx unknown

Also Published As

Publication number	Publication date
AU3096700A (en)	2000-05-22
CO5140100A1 (es)	2002-03-22
AU777393B2 (en)	2004-10-14
BRPI9914996A (pt)	2001-07-10
PE20001092A1 (es)	2000-10-31
BR9914996A (pt)	2001-07-10
AR025133A1 (es)	2002-11-13
WO2000025743A2 (en)	2000-05-11
CA2348841C (en)	2007-04-17
BRPI9914996B1 (pt)	2011-11-01
WO2000025743A3 (en)	2000-08-24
ZA200103494B (en)	2002-07-30
MY134868A (en)	2007-12-31
BRPI9914996B8 (pt)	2021-07-06
CR6351A (es)	2003-11-20
CA2348841A1 (en)	2000-05-11

Legal Events

Date	Code	Title	Description
2014-12-01	MM4A	Annulment or lapse of patent due to non-payment of fees

Publication	Publication Date	Title
US7999005B2 (en)	2011-08-16	Growth stimulant compositions
AU783538B2 (en)	2005-11-03	Pharmaceutical implant containing immediate-release and sustained-release components and method of administration
US4568536A (en)	1986-02-04	Controlled release of pharmacologically active agents from an absorbable biologically compatible putty-like composition
US4650665A (en)	1987-03-17	Controlled release of pharmacologically active agents from an absorbable biologically compatible putty-like composition
CN1263435C (zh)	2006-07-12	控制释放生物活性物质的液态聚合物组合物
RU2355385C2 (ru)	2009-05-20	Композиции пролонгированного действия с контролируемым высвобождением
CN1283990A (zh)	2001-02-14	含有氢化蓖麻油的长效注射制剂
AU2025279824A1 (en)	2026-01-15	Amorphous kinase inhibitor formulations and methods of use thereof
JP2001509146A (ja)	2001-07-10	ゲル組成物および方法
JP2005505557A (ja)	2005-02-24	持続放出医薬組成物の調製
AU710539B2 (en)	1999-09-23	Pharmaceutical compositions for the sustained release of insoluble active principles
TWI250027B (en)	2006-03-01	Improved growth stimulant compositions
JP4015184B2 (ja)	2007-11-28	疎水性剤を含有するディスペンサー
US20070166377A1 (en)	2007-07-19	Sustained-release drug formulations
US20070031500A1 (en)	2007-02-08	Long-acting solid formulation comprising triptorelin acetate
KR20020068377A (ko)	2002-08-27	멜렌게스트롤 아세테이트 및 트렌볼론 아세테이트를함유한 이식제 조성물
FI20195397A1 (en)	2020-11-15	Oral control device for controlled release
JP2005538052A (ja)	2005-12-15	注射製剤
JPH01149732A (ja)	1989-06-12	ソマトトロピン製剤
WO2000047232A1 (fr)	2000-08-17	Implant a liberation prolongee, son procede de preparation et traitement du cancer
JP4829405B2 (ja)	2011-12-07	生体活性物質の制御放出用液体ポリマー組成物
JPS63203610A (ja)	1988-08-23	複数成分からなるインプラント用の持効性医薬製剤
AU753759B2 (en)	2002-10-31	Improvements in and relating to implants for delivering B12 compounds